SFTPC Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P11686 |
---|---|
Clone Names | 100525118 |
Gene ID | 6440 |
---|---|
Other Names | Pulmonary surfactant-associated protein C, SP-C, Pulmonary surfactant-associated proteolipid SPL(Val), SP5, SFTPC, SFTP2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13684b was selected from the C-term region of SFTPC. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SFTPC |
---|---|
Synonyms | SFTP2 |
Function | Pulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. |
Cellular Location | Secreted, extracellular space, surface film. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes the pulmonary-associated surfactantprotein C (SPC), an extremely hydrophobic surfactant proteinessential for lung function and homeostasis after birth. Pulmonarysurfactant is a surface-active lipoprotein complex composed of 90%lipids and 10% proteins which include plasma proteins andapolipoproteins SPA, SPB, SPC and SPD. The surfactant is secretedby the alveolar cells of the lung and maintains the stability ofpulmonary tissue by reducing the surface tension of fluids thatcoat the lung. Multiple mutations in this gene have beenidentified, which cause pulmonary surfactant metabolism dysfunctiontype 2, also called pulmonary alveolar proteinosis due tosurfactant protein C deficiency, and are associated withinterstitial lung disease in older infants, children, and adults.Alternatively spliced transcript variants encoding differentprotein isoforms have been identified.
References
Wambach, J.A., et al. Pediatr. Res. 68(3):216-220(2010)Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010)Thouvenin, G., et al. Arch. Dis. Child. 95(6):449-454(2010)Crossno, P.F., et al. Chest 137(4):969-973(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.